Presentation Description:  Osteosarcoma is diagnosed in 600 North Americans annually, primarily in those aged 10-30 years.  Treatment cures two-thirds with initially localized disease, 25% with initially metastatic disease.  The only other reliable prognostic feature is histologic response to induction chemotherapy.  Other biologic features may predict outcome.  Some may be therapeutic targets.

Speaker:

Mark L. Bernstein, MD, FRCPC
Head, Division of Hematology-Oncology, IWK Health Center; Professor of Pediatrics
Dalhousie University, Halifax, NS
Head, Division of Hematology Oncology
IWK Health Center, Halifax, NS